Debiopharm announces oncology research advancements

12 April 2022 | Tuesday | News

Pre-clinical & clinical exploratory poster presentations to highlight oncology results with Debio 0123, xevinapant, and Multilink™ technology for antibody drug conjugates
Image Source : Public Domain

Image Source : Public Domain

Debiopharm, ( an oncology and infectious disease focused biopharmaceutical company based in Switzerland, today announced data releases on 3 investigational products including Debio 0123 (Selective WEE1 inhibitor), clinical exploratory results for xevinapant (IAP inhibitor), and 2 Multilink™ technology posters (antibody drug conjugate linker) at the 2022 Annual American Association for Cancer Research (AACR) meeting in New Orleans, Louisiana.

The AACR conference serves as the focal point of the cancer research community to gather together and share advances in oncology science. Debiopharm and their partners' poster presentations represent scientific progress in the research of these compounds leveraging novel modes of action and new delivery methods in development to treat cancer types with high unmet needs.

"Scientific cancer research is evolving quickly, bringing us the insights needed to better develop safer and more effective anti-tumor therapies. Our ultimate vision is to translate these findings into meaningful outcomes for patients in future clinical settings," explained Carolina Haefliger, Head of Translational Medicine at Debiopharm.  


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in